Markets
Lyell Immunopharma Stock Maintained at Market Outperform by Citizens: What Traders Need to Know
Citizens has reaffirmed its Market Outperform rating on Lyell Immunopharma, signaling continued conviction in the cell therapy pioneer's long-term pipeline. Here is the full technical and fundamental breakdown traders need.